Tim Freeborn

Mr. Timothy C.
Freeborn is an Analyst at Slater Investments Ltd. He joined the firm in February 2017 and serves on the Investment Committee.
Since qualifying as a Chartered Accountant, Mr. Freeborn has had a varied career.
For many years he was a City writer at The Daily Mail, he has also edited an investment newsletter and contributed to Shares Magazine.
This was followed by several years as a Stockbroking Analyst at Evolution Securities and Xcap Securities covering growth companies.
Before joining Slater Investments, he spent four years as the Chief Financial Officer of Silence Therapeutics, an Aim listed biotech company and latterly ran its laboratories in Berlin.
He received his undergraduate degree from the University College London.